Early culture conversion is a poor marker of treatment outcome among people with HIV and drug‐resistant TB

Our objective was to determine associations between early (≤2 months) culture conversion (ECC) among people with HIV and drug‐resistant tuberculosis (DRTB) in Uganda.

[1]  F. Bongomin,et al.  Gender differences among patients with drug resistant tuberculosis and HIV co-infection in Uganda: a countrywide retrospective cohort study , 2021, BMC Infectious Diseases.

[2]  M. K. Martin,et al.  High rates of culture conversion and low loss to follow-up in MDR-TB patients managed at Regional Referral Hospitals in Uganda , 2021, BMC Infectious Diseases.

[3]  M. Nabwana,et al.  Undernutrition and Treatment Success in Drug-Resistant Tuberculosis in Uganda , 2021, Infection and drug resistance.

[4]  M. Nabwana,et al.  Multidisciplinary management of difficult-to-treat drug resistant tuberculosis: a review of cases presented to the national consilium in Uganda , 2021, BMC Pulmonary Medicine.

[5]  Animut Alebel,et al.  Predictors of mortality in patients with drug-resistant tuberculosis: A systematic review and meta-analysis , 2021, PloS one.

[6]  S. Chadha,et al.  Situational analysis of the 10 high drug resistant tuberculosis burden countries two years post-UNHLM declaration: progress and setbacks in a changing landscape. , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[7]  V. Soetikno,et al.  The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis , 2021, PloS one.

[8]  M. Nabwana,et al.  Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study , 2021, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.

[9]  J. Beyene,et al.  HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis , 2021, BMC Infectious Diseases.

[10]  J. Baluku.  INTEREST 2021 conference: is Africa still hoping against hope in the fight against HIV? , 2021, Therapeutic advances in infectious disease.

[11]  Dumessa Edessa,et al.  Unfavorable outcomes to second-line tuberculosis therapy among HIV-infected versus HIV-uninfected patients in sub-Saharan Africa: A systematic review and meta-analysis , 2020, PloS one.

[12]  J. Pape,et al.  Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis , 2020, The Lancet.

[13]  L. Lecca,et al.  Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study , 2020, American journal of respiratory and critical care medicine.

[14]  B. Sahiledengle,et al.  Predictors of Time to Sputum Culture Conversion Among Drug-Resistant Tuberculosis Patients in Oromia Region Hospitals, Ethiopia , 2020, Infection and drug resistance.

[15]  C. T. Leshargie,et al.  Time to sputum culture conversion and its associated factors among multidrug-resistant tuberculosis patients in Eastern Africa: A systematic review and meta-analysis. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[16]  Alimuddin Zumla,et al.  UN General Assembly tuberculosis targets: are we on track? , 2020, The Lancet.

[17]  J. Brożek,et al.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline , 2019, American journal of respiratory and critical care medicine.

[18]  A. Telnov,et al.  What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis? , 2019, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  M. Van Hout,et al.  Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis , 2019, BMC Infectious Diseases.

[20]  R. Houben,et al.  Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling , 2019, The Lancet. Infectious diseases.

[21]  O. Ige,et al.  Time to sputum culture conversion and treatment outcome among the first cohort of multidrug resistant tuberculosis patients in a high burden country. , 2018, The Indian journal of tuberculosis.

[22]  B. Ledergerber,et al.  Comparison of Löwenstein–Jensen and BACTEC MGIT 960 culture for Mycobacterium tuberculosis in people living with HIV , 2018, HIV medicine.

[23]  B. Tessema,et al.  Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia , 2018, PloS one.

[24]  Kindie Fentahun Muchie,et al.  Time to sputum culture conversion and its determinants among Multi-drug resistant Tuberculosis patients at public hospitals of the Amhara Regional State: A multicenter retrospective follow up study , 2018, PloS one.

[25]  A. Khan,et al.  Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study. , 2018, The American journal of tropical medicine and hygiene.

[26]  E. Kurbatova,et al.  Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. , 2015, The Lancet. Respiratory medicine.

[27]  R. Gilman,et al.  Molecular Diagnosis of TB in the HIV Positive Population. , 2015, Annals of global health.

[28]  Sonya S. Shin,et al.  Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment , 2014, PloS one.

[29]  O. Oladimeji,et al.  Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria , 2014, PloS one.

[30]  A. Opio,et al.  Uganda's New National Laboratory Sample Transport System: A Successful Model for Improving Access to Diagnostic Services for Early Infant HIV Diagnosis and Other Programs , 2013, PloS one.

[31]  E. Houpt,et al.  Diagnosis and Interim Treatment Outcomes from the First Cohort of Multidrug-Resistant Tuberculosis Patients in Tanzania , 2013, PloS one.

[32]  B. Hedt-Gauthier,et al.  Outcomes of Multidrug-Resistant Tuberculosis Treatment with Early Initiation of Antiretroviral Therapy for HIV Co-Infected Patients in Lesotho , 2012, PloS one.

[33]  E. Pontali,et al.  Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India , 2011, PloS one.

[34]  J. Nkengasong,et al.  Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities , 2011, Clinical Microbiology Reviews.

[35]  U. Lalloo,et al.  Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa , 2011, PloS one.